FDA Clearance Tracker · P130022-S037
Senza Spinal Cord Stimulation (SCS) System
Last checked: Nov 20, 2026Latest source record: Mar 1, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Mar 1, 2021
Approved
Time to decision
152 days
Received Sep 30, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P130022-S037
- Device name
- Senza Spinal Cord Stimulation (SCS) System
- Applicant
- Nevro Corporation
- Applicant location
- Redwood City, CA
- Received
- Sep 30, 2020
- Decided
- Mar 1, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P130022
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for addition of OSCOR Caribe located at Santo Domingo Este, Dominican Republic as a secondary manufacturing site for the Percutaneous Leads of the Senza neuromodulation system. Pro-Tech Design & Manufacturing Inc. and Steris-Isomedix Services will continue to perform final packaging and sterilization, respectively.
Source documents
Other decisions for Nevro Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Senza Spinal Cord Stimulation (SCS) SystemPMA supplement
P130022-S042 · Decided Jan 18, 2022 · 180 days after receipt · Panel Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.